;PMID: 8669886 ;source_file_2839.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..46] = [t:0..46] ;1)sentence:[e:52..128] = [t:52..128] ;2)section:[e:132..217] = [t:132..217] ;3)section:[e:221..276] = [t:221..276] ;4)sentence:[e:280..519] = [t:280..519] ;5)sentence:[e:520..638] = [t:520..638] ;6)sentence:[e:639..900] = [t:639..900] ;7)sentence:[e:901..1048] = [t:901..1048] ;8)sentence:[e:1049..1268] = [t:1049..1268] ;9)section:[e:1272..1316] = [t:1272..1316] ;section 0 Span:0..46 ;Anticancer Res. 1995 Nov-Dec;15(6B):2899-905. (SEC (FRAG (NNP:[0..10] Anticancer) (NNP:[11..14] Res) (.:[14..15] .) (CD:[17..21] 1995) (NNP:[22..29] Nov-Dec) (::[29..30] ;) (CD:[30..32] 15) (-LRB-:[32..33] -LRB-) (NN:[33..35] 6B) (-RRB-:[35..36] -RRB-) (::[36..37] :) (CD:[37..45] 2899-905) (.:[45..46] .))) ;sentence 1 Span:52..128 ;N-myc protein expression in human breast carcinoma: prognostic implications. ;[52..57]:gene-protein:"N-myc" ;[86..102]:malignancy-type:"breast carcinoma" (SENT (NP-HLN (NP (NP (NN:[52..57] N-myc) (NN:[58..65] protein) (NN:[66..76] expression)) (PP (IN:[77..79] in) (NP (JJ:[80..85] human) (NN:[86..92] breast) (NN:[93..102] carcinoma)))) (::[102..103] :) (NP (JJ:[104..114] prognostic) (NNS:[115..127] implications)) (.:[127..128] .))) ;section 2 Span:132..217 ;Mizukami Y, Nonomura A, Takizawa T, Noguchi M, Michigishi T, Nakamura S, ;Ishizaki T. (SEC (FRAG (NNP:[132..140] Mizukami) (NNP:[141..142] Y) (,:[142..143] ,) (NNP:[144..152] Nonomura) (NNP:[153..154] A) (,:[154..155] ,) (NNP:[156..164] Takizawa) (NNP:[165..166] T) (,:[166..167] ,) (NNP:[168..175] Noguchi) (NNP:[176..177] M) (,:[177..178] ,) (NNP:[179..189] Michigishi) (NNP:[190..191] T) (,:[191..192] ,) (NNP:[193..201] Nakamura) (NNP:[202..203] S) (,:[203..204] ,) (NNP:[206..214] Ishizaki) (NNP:[215..216] T) (VBD:[216..217] .))) ;section 3 Span:221..276 ;Pathology Section, Kanazawa University Hospital, Japan. (SEC (FRAG (NNP:[221..230] Pathology) (NNP:[231..238] Section) (,:[238..239] ,) (NNP:[240..248] Kanazawa) (NNP:[249..259] University) (NNP:[260..268] Hospital) (,:[268..269] ,) (NNP:[270..275] Japan) (.:[275..276] .))) ;sentence 4 Span:280..519 ;The overexpression of N-myc gene and its protein products has been thought to ;be limited to cases of neuroblastoma, retinoblastoma and small cell lung ;carcinoma, but there is increasing evidence of its wider distribution in ;human tumors. ;[302..307]:gene-rna:"N-myc" ;[317..337]:gene-protein:"its protein products" ;[382..395]:malignancy-type:"neuroblastoma" ;[397..411]:malignancy-type:"retinoblastoma" ;[416..441]:malignancy-type:"small cell lung carcinoma" (SENT (S (S (NP-SBJ-1 (NP (DT:[280..283] The) (NN:[284..298] overexpression)) (PP (IN:[299..301] of) (NP (NP (NN:[302..307] N-myc) (NN:[308..312] gene)) (CC:[313..316] and) (NP (PRP$:[317..320] its) (NN:[321..328] protein) (NNS:[329..337] products))))) (VP (VBZ:[338..341] has) (VP (VBN:[342..346] been) (VP (VBN:[347..354] thought) (S (NP-SBJ-1 (-NONE-:[354..354] *)) (VP (TO:[355..357] to) (VP (VB:[358..360] be) (VP (VBN:[362..369] limited) (NP-1 (-NONE-:[369..369] *)) (PP-CLR (TO:[370..372] to) (NP (NP (NNS:[373..378] cases)) (PP (IN:[379..381] of) (NP (NP (NN:[382..395] neuroblastoma)) (,:[395..396] ,) (NP (NN:[397..411] retinoblastoma)) (CC:[412..415] and) (NP (NML (JJ:[416..421] small) (NN:[422..426] cell)) (NN:[427..431] lung) (NN:[432..441] carcinoma)))))))))))))) (,:[441..442] ,) (CC:[444..447] but) (S (NP-SBJ (EX:[448..453] there)) (VP (VBZ:[454..456] is) (NP-PRD (NP (VBG:[457..467] increasing) (NN:[468..476] evidence)) (PP (IN:[477..479] of) (NP (PRP$:[480..483] its) (JJR:[484..489] wider) (NN:[490..502] distribution)))) (PP (IN:[503..505] in) (NP (JJ:[506..511] human) (NNS:[512..518] tumors))))) (.:[518..519] .))) ;sentence 5 Span:520..638 ;This study showed that the protein of N-myc gene is associated in normal, ;benign and malignant human breast tissues. ;[544..555]:gene-protein:"the protein" ;[559..564]:gene-rna:"N-myc" (SENT (S (NP-SBJ (DT:[520..524] This) (NN:[526..531] study)) (VP (VBD:[532..538] showed) (SBAR (IN:[539..543] that) (S (NP-SBJ-1 (NP (DT:[544..547] the) (NN:[548..555] protein)) (PP (IN:[556..558] of) (NP (NN:[559..564] N-myc) (NN:[565..569] gene)))) (VP (VBZ:[570..572] is) (VP (VBN:[573..583] associated) (NP-1 (-NONE-:[583..583] *)) (PP-LOC (IN:[584..586] in) (NP (NP (JJ:[587..593] normal) (NML-2 (-NONE-:[593..593] *P*))) (,:[593..594] ,) (NP (JJ:[595..601] benign) (NML-2 (-NONE-:[601..601] *P*))) (CC:[602..605] and) (NP (JJ:[607..616] malignant) (NML-2 (JJ:[617..622] human) (NN:[623..629] breast) (NNS:[630..637] tissues)))))))))) (.:[637..638] .))) ;sentence 6 Span:639..900 ;We found that N-myc oncoprotein is overexpressed in most breast carcinomas ;and that N-myc overexpression is significantly correlated with clinical ;stage, and histological grading of the tumors, and, more importantly with ;the clinical outcome of the patients. ;[653..658]:gene-protein:"N-myc" ;[697..714]:malignancy-type:"breast carcinomas" ;[724..729]:gene-protein:"N-myc" (SENT (S (NP-SBJ (PRP:[639..641] We)) (VP (VBD:[642..647] found) (SBAR (SBAR (IN:[648..652] that) (S (NP-SBJ-1 (NN:[653..658] N-myc) (NN:[659..670] oncoprotein)) (VP (VBZ:[671..673] is) (VP (VBN:[674..687] overexpressed) (NP-1 (-NONE-:[687..687] *)) (PP-LOC (IN:[689..691] in) (NP (JJS:[692..696] most) (NN:[697..703] breast) (NNS:[704..714] carcinomas))))))) (CC:[715..718] and) (SBAR (IN:[719..723] that) (S (NP-SBJ-2 (NN:[724..729] N-myc) (NN:[730..744] overexpression)) (VP (VBZ:[745..747] is) (ADVP (RB:[748..761] significantly)) (VP (VBN:[763..773] correlated) (NP-2 (-NONE-:[773..773] *)) (PP-CLR (PP (IN:[774..778] with) (NP (NP (NP (JJ:[779..787] clinical) (NN:[788..793] stage)) (,:[793..794] ,) (CC:[795..798] and) (NP (JJ:[799..811] histological) (NN:[812..819] grading))) (PP (IN:[820..822] of) (NP (DT:[823..826] the) (NNS:[827..833] tumors))))) (,:[833..834] ,) (CC:[835..838] and) (,:[838..839] ,) (PP (ADVP (RBR:[841..845] more) (RB:[846..857] importantly)) (IN:[858..862] with) (NP (NP (DT:[863..866] the) (JJ:[867..875] clinical) (NN:[876..883] outcome)) (PP (IN:[884..886] of) (NP (DT:[887..890] the) (NNS:[891..899] patients)))))))))))) (.:[899..900] .))) ;sentence 7 Span:901..1048 ;Analysis of DNA, mRNA and protein levels suggested that the high N-myc ;expression in breast cancer occurs without concomitant gene amplification. ;[967..972]:gene-generic:"N-myc" ;[987..1001]:malignancy-type:"breast cancer" ;[1034..1047]:variation-type:"amplification" (SENT (S (NP-SBJ (NP (NN:[901..909] Analysis)) (PP (IN:[910..912] of) (NP (NP (NN:[913..916] DNA)) (,:[916..917] ,) (NP (NN:[919..923] mRNA)) (CC:[924..927] and) (NP (NN:[928..935] protein) (NNS:[936..942] levels))))) (VP (VBD:[943..952] suggested) (SBAR (IN:[953..957] that) (S (NP-SBJ (NP (DT:[958..961] the) (JJ:[962..966] high) (NN:[967..972] N-myc) (NN:[973..983] expression)) (PP (IN:[984..986] in) (NP (NN:[987..993] breast) (NN:[995..1001] cancer)))) (VP (VBZ:[1002..1008] occurs) (PP (IN:[1009..1016] without) (NP (JJ:[1017..1028] concomitant) (NN:[1029..1033] gene) (NN:[1034..1047] amplification))))))) (.:[1047..1048] .))) ;sentence 8 Span:1049..1268 ;The finding of a direct inverse correlation between N-myc overexpression and ;the prognosis of patients with breast carcinoma suggests that N-myc ;expression may be useful as a prognostic factor in human breast cancer. ;[1102..1107]:gene-generic:"N-myc" ;[1159..1175]:malignancy-type:"breast carcinoma" ;[1190..1195]:gene-generic:"N-myc" ;[1254..1267]:malignancy-type:"breast cancer" (SENT (S (NP-SBJ (NP (DT:[1049..1052] The) (NN:[1053..1060] finding)) (PP (IN:[1061..1063] of) (NP (NP (DT:[1064..1065] a) (JJ:[1066..1072] direct) (JJ:[1074..1081] inverse) (NN:[1082..1093] correlation)) (PP (IN:[1094..1101] between) (NP (NP (NN:[1102..1107] N-myc) (NN:[1108..1122] overexpression)) (CC:[1123..1126] and) (NP (NP (DT:[1127..1130] the) (NN:[1131..1140] prognosis)) (PP (IN:[1141..1143] of) (NP (NP (NNS:[1144..1152] patients)) (PP (IN:[1154..1158] with) (NP (NN:[1159..1165] breast) (NN:[1166..1175] carcinoma))))))))))) (VP (VBZ:[1176..1184] suggests) (SBAR (IN:[1185..1189] that) (S (NP-SBJ (NN:[1190..1195] N-myc) (NN:[1196..1206] expression)) (VP (MD:[1207..1210] may) (VP (VB:[1211..1213] be) (ADJP-PRD (JJ:[1214..1220] useful)) (PP (IN:[1221..1223] as) (NP (DT:[1224..1225] a) (JJ:[1227..1237] prognostic) (NN:[1238..1244] factor))) (PP (IN:[1245..1247] in) (NP (JJ:[1248..1253] human) (NN:[1254..1260] breast) (NN:[1261..1267] cancer)))))))) (.:[1267..1268] .))) ;section 9 Span:1272..1316 ;PMID: 8669886 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1272..1276] PMID) (::[1276..1277] :) (CD:[1278..1285] 8669886) (NN:[1286..1287] -LSB-) (NNP:[1287..1293] PubMed) (::[1294..1295] -) (NN:[1296..1303] indexed) (IN:[1304..1307] for) (NNP:[1308..1315] MEDLINE) (-RRB-:[1315..1316] -RSB-)))